News for hackers. Stuff that matters.
Re:AI in drug discovery is overhyped: examples from AstraZen... by jostmey on Friday January 05, 2018 @02:36PM (#16081005)
For the most part, I agree with the article's premise.

But they were pretty unfair to the Stanford lab (Vijay Pande). The Stanford team is using graph convolutions to process molecular structures. The article complains that the Stanford team is biased because they are not using sequences to represent the molecular structures. But this actually makes a lot of sense because molecular structures are graphs. The article then goes on to say that the Stanford team has an agenda to get everyone to use deepchem instead of TensorFlow or PyTorch. But TensorFlow is a dependency in deepchem, and deepchem looks like a bunch of useful tools wrapped around TensorFlow.

I'm not buying the articles arguments

Re:AI in drug discovery is overhyped: examples from AstraZen... by blueblob on Friday January 05, 2018 @02:47PM (#16081079)
Agreed. Just because you don't compare your model to another model doesn't mean you're hiding something and it's irresponsible to pretend that's the case. Perhaps the author should have run char-cnn against data instead of making baseless accusations.

On the whole, a lot of the arguments are realistic of ML in general. There is far too much focus on individual problems and the accuracy measure without enough focus on the interpretation of the accuracy, how well it will really generalize, etc.

Re:AI in drug discovery is overhyped: examples from AstraZen... by mostafab on Friday January 05, 2018 @05:52PM (#16082486)
In general, you are right. But in this particular case, char-CNN is the standard used by many people, Stanford included. It is not sophisticated at all.

Look at the big list of exotic models they tried: http://moleculenet.ai/models

For me, this omission is a negligence. It is selective laziness.

The author (me) does not have 20 PhD students, postdocs and startuppers under his hand, to do the job for Stanford. With my limited resources, it is more cost-effective to do my job against Stanford ;)

Re:AI in drug discovery is overhyped: examples from AstraZen... by dekhn on Saturday January 06, 2018 @10:18AM (#16085593)
It sounds like you have axe to grind against well-funded professors, not that you actually have a valid argument.
Re:AI in drug discovery is overhyped: examples from AstraZen... by mostafab on Saturday January 06, 2018 @08:25PM (#16088530)
This professor gave an argument in his paper. I gave a refutation. If you agree with him that char-CNN was a sophisticated model in early 2017, then you are not well-informed about the situation in deep learning.

The MoleculeNet co-author gave another argument in the comments. My refutation is that you can't claim to lack time after 8*20 man-months have passed.

Re:AI in drug discovery is overhyped: examples from AstraZen... by mostafab on Friday January 05, 2018 @05:41PM (#16082412)
Author here

1. I agree that graph convolutions make a lot of sense. However, it is not shown yet that they are better than SMILES, although it might just be a matter of time. A lot of graph variants are possible, or maybe we should look at molecules not as graphs, but as quantum objects (See the other Stanford paper on atom convolutions).

2. Yes, Deepchem is built on top of Tensorflow. This additional layer looks useful, but is it really the case? Using standard NLP models is simpler than using deepchem models, and NLP models might still be the state-of-the-art for chemistry tasks, via SMILES (until we get a reasonably comprehensive benchmark, which MoleculeNet is not).

I am not buying into a chemistry-specific library, until it is shown to be really necessary.

Re:AI in drug discovery is overhyped: examples from AstraZen... by msamwald on Friday January 05, 2018 @05:52PM (#16082484)
Well my group and others are toying with applying RNNs to permuted SMILES strings; if it ends up being better, we will find out some time this year.